- Home
- AEE vs ILMN Comparison
AEE vs ILMN Comparison
Compare AEE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEE | ILMN |
|---|---|---|
| Founded | 1901 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5B | 20.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AEE | ILMN |
|---|---|---|
| Price | $101.08 | $134.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | $110.00 | ★ $117.31 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 02-12-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ 22.35 | N/A |
| EPS | ★ 5.21 | 4.46 |
| Revenue | ★ $8,635,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $5.92 | $2.24 |
| P/E Ratio | ★ $19.37 | $30.12 |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $86.81 | $68.70 |
| 52 Week High | $106.73 | $153.06 |
Technical Indicators
Market Signals| Indicator | AEE | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 57.78 |
| Support Level | $99.21 | $132.93 |
| Resistance Level | $99.88 | $135.95 |
| Average True Range (ATR) | 1.22 | 3.28 |
| MACD | 0.39 | -0.85 |
| Stochastic Oscillator | 90.38 | 50.37 |
Price Performance
Historical ComparisonAbout AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and 800,000 natural gas customers across its two service territories.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.